Precision Medicine in Asthma: Eosinophils and Biologics

20 Nov 2026 11:00 11:15
Min Suk Yang Speaker Republic of Korea
Asthma is not a single disease. Cluster and molecular studies consistently identify a type 2-high endotype, driven by epithelial alarmins, IL-4, IL-5 and IL-13, whereas type 2-low asthma remains poorly defined. Blood eosinophils and FeNO each predict exacerbations independently of clinical risk factors, and together identify the highest-risk patients. Because corticosteroids suppress both, low values on treatment should be repeated before a patient is labelled type 2-low. Six monoclonal antibodies target IgE, IL-5 or its receptor, IL-4Rα and TSLP. All reduce exacerbations, and several spare oral corticosteroids, yet registries show clinical remission in only one in four or five patients, and cost shapes real-world use. With no overall winner, the choice rests on predictive biomarkers and comorbidities. Beyond the blood count, CT mucus plugs, exacerbation phenotyping, molecular profiling and treatable traits are extending precision care, with remission, more likely before steroid dependence, as the goal.